QUESTRAN LIGHT Drug Patent Profile
✉ Email this page to a colleague
When do Questran Light patents expire, and what generic alternatives are available?
Questran Light is a drug marketed by Bristol Myers and is included in one NDA.
The generic ingredient in QUESTRAN LIGHT is cholestyramine. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the cholestyramine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Questran Light
A generic version of QUESTRAN LIGHT was approved as cholestyramine by EPIC PHARMA LLC on August 15th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QUESTRAN LIGHT?
- What are the global sales for QUESTRAN LIGHT?
- What is Average Wholesale Price for QUESTRAN LIGHT?
Summary for QUESTRAN LIGHT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 9 |
| DailyMed Link: | QUESTRAN LIGHT at DailyMed |
Recent Clinical Trials for QUESTRAN LIGHT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre Hospitalier Universitaire de Nice | N/A |
| National Cancer Institute (NCI) | Phase 1 |
| City of Hope Medical Center | Phase 1 |
US Patents and Regulatory Information for QUESTRAN LIGHT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers | QUESTRAN LIGHT | cholestyramine | POWDER;ORAL | 019669-001 | Dec 5, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bristol Myers | QUESTRAN LIGHT | cholestyramine | POWDER;ORAL | 019669-003 | Dec 5, 1988 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
